<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436761</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000529361</org_study_id>
    <secondary_id>PSCI-18589</secondary_id>
    <nct_id>NCT00436761</nct_id>
  </id_info>
  <brief_title>Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors</brief_title>
  <official_title>A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor umbilical cord blood stem cell transplant helps
      stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting
      the donor's stem cells when they do not exactly match the patient's blood. The donated stem
      cells may replace the patient's immune cells and help destroy any remaining tumor cells
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
      immune response against the body's normal cells. Giving cyclosporine and methylprednisolone
      after the transplant may stop this from happening.

      PURPOSE: This phase I trial is studying the side effects of busulfan, melphalan, and
      antithymocyte globulin followed by umbilical cord blood transplant in treating young patients
      with refractory or relapsed malignant solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Examine the impact of the use of killer cell immunoglobulin-like receptor
           (KIR)-mismatched umbilical cord blood as a source of hematopoietic stem cells, after
           busulfan, melphalan, and anti-thymocyte globulin in pediatric patients with relapsed or
           refractory solid tumors.

        -  Determine the toxicity of this regimen, in terms of incidence of grade 3-4 acute
           graft-versus-host disease, donor/host chimerism, and cellular immunity against tumor
           cell lines, in these patients.

      OUTLINE:

        -  Transplantation: Patients receive busulfan orally or IV every 6 hours on days -8 to -5,
           anti-thymocyte globulin IV over 6 hours on days -4 to -1, and melphalan IV over 15-20
           minutes on days -4 to -2. Patients undergo allogeneic umbilical cord blood stem cell
           infusion on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on
           day 7 and continuing until blood counts recover.

        -  Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV over 1 hour or
           orally twice daily on days -1 to 180 and methylprednisolone IV or orally once or twice
           daily on days 5 - 49.

      Blood samples are collected periodically for immunophenotyping and flow cytometric analysis
      (including interferon gamma and other TH1 and TH2 cytokines).

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of graft-versus-host disease</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor/host chimerism status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune function post-transplant</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of malignant solid tumor

          -  Relapsed or refractory disease

               -  No isolated local recurrence of disease (in the site of the primary tumor) &gt; 1
                  year after completing therapy

          -  No brain tumors or brain metastases

          -  Unrelated cord blood donor available

               -  May be HLA 6/6 matched (HLA-A, -B, -DR) OR mismatched for 1, 2, or 3 of these HLA
                  loci, but must be mismatched for HLA-C group as indicated by their following
                  killer cell immunoglobulin-like receptor (KIR) group specificity:

                    -  KIR2DL1

                         -  Cw 2

                         -  Cw 0307

                         -  Cw 4, 5, 6

                         -  Cw 0707, 0709

                         -  Cw 1204, 1205

                         -  All other Cw 15 alleles

                         -  Cw 1602

                         -  Cw 17

                         -  Cw 18

                    -  KIR2DL2

                         -  Cw 1

                         -  All other Cw 3 alleles

                         -  All other Cw 7 alleles

                         -  Cw 8

                         -  Cw 1202, 1203, 1206

                         -  Cw 1301

                         -  Cw 1402, 1403

                         -  Cw 1507

                         -  Cw 1601, 1604

          -  Cord blood specimen must have ≥ 1 x 10^7 nucleated cells/kg patient ideal body weight

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Lansky PS 70-100%

          -  Cardiac ejection fraction ≥ 50%

          -  Creatinine clearance ≥ 50%

          -  Bilirubin ≤ 3.0 mg/dL

          -  DLCO ≥ 70% OR O_2 saturation ≥ 95% on room air

        PRIOR CONCURRENT THERAPY:

          -  Prior autologous stem cell transplantation allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G. Lucas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

